Drugplain

Potassium Chloride in Dextrose 5 g/100mL

Potassium Chloride and Dextrose Monohydrate · INJECTION, SOLUTION · Baxter Healthcare Company

No Recall HistoryCurrently in Shortage
Plain English

Potassium Chloride in Dextrose is a injection, solution containing potassium chloride and dextrose monohydrate at 5 g/100mL, taken intravenous. Manufactured by Baxter Healthcare Company.

Key Facts

Brand Name
Potassium Chloride in Dextrose
Generic Name
Potassium Chloride and Dextrose Monohydrate
NDC Code (Product)
0338-0683
Manufacturer
Baxter Healthcare Company
Strength
5 g/100mL
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Marketing Status
Application #
NDA017634
Marketing Start
02/01/1979

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

death16 reports
infusion related reaction4 reports
product label confusion4 reports
product packaging confusion4 reports
dyspnoea3 reports
febrile neutropenia3 reports
product name confusion3 reports
renal ischaemia3 reports
anaemia2 reports
blood potassium increased2 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE This solution is indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories.

Dosage & Administration

DOSAGE AND ADMINISTRATION This solution should be administered only by intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (usually up to 40 mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hour dose should not generally exceed 200 mEq of potassium. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS . Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic techniq

Warnings

WARNINGS Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. To avoid potassium intoxication, do not infuse these solutions rapidly. In patients with severe renal insufficiency or adrenal insufficiency, administration of potassium chloride may cause potassium intoxication. In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention. The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

Contraindications

CONTRAINDICATIONS Solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered.

Drug Interactions

Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Adverse Reactions

ADVERSE REACTIONS Reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. Nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest. Potassium-containing solutions are intrinsically irritating to tissues. Therefore, extreme care should be taken to avoid perivascular infiltration. Local tissue necrosis and subsequent sloughing may result if extravasation occurs. Chemical phlebitis

Frequently Asked Questions

What is Potassium Chloride in Dextrose used for?

Potassium Chloride in Dextrose contains Potassium Chloride and Dextrose Monohydrate. It is a injection, solution taken intravenous. Consult your doctor for specific uses.

Is Potassium Chloride in Dextrose a controlled substance?

Potassium Chloride in Dextrose is not classified as a controlled substance by the DEA.

What is the generic name for Potassium Chloride in Dextrose?

The generic name for Potassium Chloride in Dextrose is Potassium Chloride and Dextrose Monohydrate. There are no other listed brand versions of Potassium Chloride and Dextrose Monohydrate.

What is the NDC code for Potassium Chloride in Dextrose 5 g/100mL?

The NDC (National Drug Code) for Potassium Chloride in Dextrose 5 g/100mL is 0338-0683, listed by Baxter Healthcare Company.

Product NDC

0338-0683

Package NDC

0338-0683-04

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)